Hidradenitis secondary to nirogacestat, a recently approved desmoid tumor medication

Summary

Hidradenitis suppurativa (HS) is a poorly understood chronic inflammatory disorder of the hair follicle that affects apocrine gland-rich and intertriginous areas. HS is a clinical diagnosis characterized by deep seated, painful nodules, frequently in the axilla or groin, that may spontaneously rupture and drain malodorous, purulent, or sanguineous material. Drug-associated HS has been previously reported in the literature implicating new immunomodulating medications such adalimumab, infliximab, vemurafenib, rituximab, and tocilizumab.1 However, we present a case of HS secondary to an entirely new class of medication, gamma secretase (GS) inhibitors.